Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

3 clinical studies listed.

Filters:

Cutaneous T-cell Lymphoma (CTCL)

Tundra lists 3 Cutaneous T-cell Lymphoma (CTCL) clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

ACTIVE NOT RECRUITING

NCT06485219

A Phase IIa Clinical Study of Purinostat Mesylate for Injection in Patients With Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Primary Objective To evaluate the preliminary efficacy of Purinostat Mesylate for Injection in patients with relapsed or refractory Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). Secondary Objectives 1. To evaluate the safety and tolerability of Purinostat Mesylate for Injection in patients with relapsed or refractory PTCL and CTCL. 2. To evaluate the population pharmacokinetic characteristics of Purinostat Mesylate for Injection in patients with relapsed or refractory PTCL and CTCL. Exploratory Objective To investigate the relationship between tumor biomarkers and the therapeutic efficacy/safety profile of Purinostat Mesylate for Injection.

Gender: All

Ages: 18 Years - Any

Updated: 2026-02-06

2 states

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Cutaneous T-cell Lymphoma (CTCL)
RECRUITING

NCT06914037

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies

Gender: All

Ages: 18 Years - 70 Years

Updated: 2025-04-06

1 state

Peripheral T-cell Lymphoma
Cutaneous T-cell Lymphoma (CTCL)
NHL (Non-Hodgkin Lymphoma)
ACTIVE NOT RECRUITING

NCT04072458

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.

Gender: All

Ages: 18 Years - Any

Updated: 2025-02-24

4 states

Mantle Cell Lymphoma
Peripheral T-cell Lymphoma (PTCL)
Cutaneous T-cell Lymphoma (CTCL)
+7